

Figure 1



Figure 2A


ATCCGCTACCACCGCTACCACGGGCGCTCGGCCACCGTGTGGTCGCTGGGCGTG 1134
I R Y H R Y H G R S A T V W S L G V
CTTCTCTACGATATGGTGTGTGGGGACATCCCCTTCGAGCAGGACGAGGAGATC 1188
L L Y D M V C G D I P F E Q D E E I
CTCCGAGGCCGCCTGCTCTTCCGGAGGAGGGTCTCTCCAGAGTGCCAGCAGCTG 1242
L R G R L L F R R R V S P E C Q Q L
ATCCGGTGGTGCCTGTCCCTGCGGCCCTCAGAGCGGCCGTCGCTGGATCAGATT 1296
I R W C L S L R P S E R P S L D Q I
GCGGCCCATCCCTGGATGCTGGGGGGCTGACGGGGGGCGCCCCGGAGAGCTGTGAC 1350
A A H P W M L G A D G G A P E S C D
CTGCGGCTGTGCACCCTCGACCCTGATGACGTGGCCAGCACCACGTCCAGCAGC 1404
L R L C T L E P D D V A S T T S S S
GAGAGCTTGTGAGGAGCTGCACCTGACTGGGAGCTAGGGGACCACCTGCCTTGG 1458
E S L *
CCAGACCTGGGACGCCCCCAGACCCTGACTTTTTCCTGCGTGGGCCGTCTCCTC 1512
CTGCGGAAGCAGTGACCTCTGACCCCTGGTGACCTTCGCTTTGAGTGCCTTTTG 1566
AACGCTGGTCCCGCGGGACTTGGTTTTCTCAAGCTCTGTCTGTCCAAAGACGCT 1620
CCGGTCGAGGTCCCGCCTGCCCTGGGTGGATACTTGAACCCCAGACGCCCCTCT 1674
GTGCTGCTGTGTCCGGAGGCGGCCTTCCCATCTGCCTGCCCACCCGGAGCTCTT 1728
TCCGCCGGCGCAGGGTCCCAAGCCCACCTCCCGCCCTCAGTCCTGCGGTGTGCG 1782
TCTGGGCAGGTCCTGCACACACAATGCAAGTCCTGGCCTCCGCGCCCCGCCCCGCC 1836
CACGCGAGCCGTACCCGCCGCCAACTCTGTTATTTATGGTGTGACCCCCTGGAG 1890
GTGCCCTCGGCCCCACCGGGGCTATTTATTGTTTAATTTATTTGTTGAGGTTATT 1944
TCCTCTGAGCAGTCTGCCTCTCCCAAGCCCCAGGGGACAGTGGGGAGGCAGGGG 1998
AGGGGGTGGCTGTGGTCCAGGGACCCCAGGCCCTGATTCCTGTGCCTGGCGTCT 2052
GTCCTGGCCCCCGCCTGTCAGAAGATGAACATGTATAGTGGCTAACTTAAGGGGA 2106
GTGGGTGACCCTGACACTTCCAGGCACTGTGCCCAGGGTTTGGGTTTTAAATTA 2160
TTGACTTTGTACAGTCTGCTTGTGGGCTCTGAAAGCTGGGGGTGGGGCCAGAGCC 2214
TGAGCGTTTAATTTATTCAGTACCTGTGTTTGTGTGAATGCGGTGTGTGCAGGC 2268
ATCGCAGATGGGGGTTCTTTCAGTTCAAAAGTGAGATGTCTGGAGATCATATTT 2322
TTTTATACAGGTATTTCAATTAAAATGTTTTTGTACATAAAAAAAAAAAAAAAA 2376
AAAAAAAAAAAAAAAAA 3'

Figure 2B

```
                    10         20         30         40         50
HUMAN     1 MLLSKFGSLA HLCGPGGVDH LPVKILQPAK ADKESFEKAY QVGAVLGSGG  50
RAT       1 MLLSKFGSLA HLCGPGGVDH LPVKILQPAK ADKESFEKVY QVGAVLGSGG  50
MOUSE     1 MLLSKFGSLA HLCGPGGVDH LPVKILQPAK ADKESFEKVY QVGAVLGSGG  50

                    60         70         80         90        100
HUMAN    51 FGTVYAGSRI ADGLPVAVKH VVKERVTEWG SLGGATVPLE VVLLRKVGAA 100
RAT      51 FGTVYAGSRI ADGLPVAVKH VVKERVTEWG SLGGMAVPLE VVLLRKVGAA 100
MOUSE    51 FGTVYAGSRI ADGLPVAVKH VVKERVTEWG SLGGVAVPLE VVLLRKVGAA 100

                   110        120        130        140        150
HUMAN   101 GGARGVIRLL DWFERPDGFL LVLERPEPAQ DLFDFITERG ALDEPLARRF 150
RAT     101 GGARGVIRLL DWFERPDGFL LVLERPEPAQ DLFDFITERG ALDEPLARRF 150
MOUSE   101 GGARGVIRLL DWFERPDGFL LVLERPEPAQ DLFDFITERG ALDEPLARRF 150

                   160        170        180        190        200
HUMAN   151 FAQVLAAVRH CHSCGVVHRD IKDENLLVDL RSGELKLIDF GSGALLKDTV 200
RAT     151 FAQVLAAVRH CHNCGVVHRD IKDENLLVDL RSGELKLIDF GSGAVLKDTV 200
MOUSE   151 FAQVLAAVRH CHNCGVVHRD IKDENLLVDL RSGELKLIDF GSGAVLKDTV 200

                   210        220        230        240        250
HUMAN   201 YTDFDGTRVY SPPEWIRYHR YHGRSATVWS LGVLLYDMVC GDIPFEQDEE 250
RAT     201 YTDFDGTRVY SPPEWIRYHR YHGRSATVWS LGVLLYDMVC GDIPFEQDEE 250
MOUSE   201 YTDFDGTRVY SPPEWIRYHR YHGRSATVWS LGVLLYDMVC GDIPFEQDEE 250

                   260        270        280        290        300
HUMAN   251 ILRGRLLFRR RVSPECQQLI RWCLSLRPSE RPSLDQIAAH PWMLGADGGA 300
RAT     251 ILRGRLFFRR RVSPECQQLI EWCLSLRPSE RPSLDQIAAH PWMLGTEGSV 300
MOUSE   251 ILRGRLFFRR RVSPECQQLI EWCLSLRPSE RPSLDQIAAH PWMLGTEGSV 300

                   310        320
HUMAN   301 PESCDLRLCT LDPDDVASTT SSSESL
RAT     301 PENCDLRLCA LDTDDGASTT SSSESL
MOUSE   301 PENCDLRLCA LDTDDGASTT SSSESL
```

Figure 3

```
                    10                  20                  30                  40                  50
Pim-1     1 MLLSKINSLA HL-RAAPQND LHATKLAPGK -EKEPLESQY QVGPLLGSGG  50
Pim-2     1 MLTKPLQ--- ---GPPAP  PGTPTPPPGG KDRBAFEAEY RLGPLLGKGG  50
Pim-3     1 MLLSKFGSLA HLCGPGGVDH LPVKILQPAK ADKESFEKAY QVGAVLGSGG  50

                    60                  70                  80                  90                  100
Pim-1    51 FGSVYSGIRV SDNLPVAIKH VEKDRISDWG ELPNGTRVPM EVVLLKKVSS 100
Pim-2    51 FGTVFAGHRL TDRLQVAIKV IPRNRVLGWS PLSDSVTCPL EVALLWKVGA 100
Pim-3    51 FGTVYAGSRI ADGLPVAVKH VVKERVTEWG SL-GGATVPL EVVLLRKVGA 100

                    110                 120                 130                 140                 150
Pim-1   101 --GFSGVIRL LDWFERPDSF VLILERPEPV QDLFDFITER GALQEELARS 150
Pim-2   101 GGGHPGVIRL LDWFETQEGF MLVLERPLPA QDLFDYITEK GPLGEGPSRC 150
Pim-3   101 AGGARGVIRL LDWFERPDGF LLVLERPEPA QDLFDFITER GALDEPLARR 150

                    160                 170                 180                 190                 200
Pim-1   151 FFWQVLEAVR HCHNCGVLHR DIKDENILID LNRGELKLID FGSGALLKDT 200
Pim-2   151 FFGQVVAAIQ HCHSRGVVHR DIKDENILID LRRGCAKLID FGSGALLHDE 200
Pim-3   151 FFAQVLAAVR HCHSCGVVHR DIKDENLLVD LRSGELKLID FGSGALLKDT 200

                    210                 220                 230                 240                 250
Pim-1   201 VYTDFDGTRV YSPPEWIRYH RYHGRSAAVW SLGILLYDMV CGDIPFEHDE 250
Pim-2   201 PYTDFDGTRV YSPPEWISRH QYHALPATVW SLGILLYDMV CGDIPFERDQ 250
Pim-3   201 VYTDFDGTRV YSPPEWIRYH RYHGRSATVW SLGVLLYDMV CGDIPFEQDE 250

                    260                 270                 280                 290                 300
Pim-1   251 EIIRGQVFFR QRVSSECQHL IRWCLALRPS DRPTFEEIQN HPWMQDVLL- 300
Pim-2   251 EILEAELHFP AHVSPDCCAL IRRCLAPKPS SRPSLEEILL DPWMQTPAED 300
Pim-3   251 EILRGRLLFR RRVSPECQQL IRWCLSLRPS ERPSLDQIAA HPWMLGADGG 300

                    310                 320                 330                 340
Pim-1   301 P----QET AEIHL---- ----HSLSPG P-------      SK
Pim-2   301 VTPQPLQRRP CPFGLVLATL SLAWPGLAPN GQKSHPMAMS QG
Pim-3   301 A----PES CDLRL---- ----CTLDPD DVASTTSSSE SL
```

Figure 4



Figure 5



Figure 6



Figure 7


2
1
0
CELL SURVIVAL RATE
LIPOFECTAMINE 2000
RANDOM RNA FRAGMENT
Pim-3 siRNA
*
*
0
1
2
3
4
*p<0. 005
ELAPSED TIME (DAY)

Figure 8



Figure 9


TREATMENT WITH
LIPOFECTAMINE ALONE
RANDOM RNA
FRAGMENT
Pim-3 siRNA
THE NUMBER OF CELLS
0 80 160 240 320 400
0 200 400 600 800 1000
PROPIDIUM IODINE

Figure 10